Yang Yongkun, Li Yuan, Liu Weifeng, Xu Hairong, Niu Xiaohui
Department of Orthopedic Oncology, Beijing Ji Shui Tan Hospital, Peking University, Beijing, People's Republic of China.
Medicine (Baltimore). 2018 Dec;97(52):e13730. doi: 10.1097/MD.0000000000013730.
To analyze the clinical results and related factors of further surgical treatment for recurrent sacral chordomas.Chordomas are rare primary malignant tumors with a high recurrence rate. The treatment of recurrent tumors is difficult and controversial. Contamination by previous operations and disturbed local anatomical structures may increase the risk of reoperation. Most previous studies have focused on the primary tumor; there are very few reports on the clinical diagnosis, treatment, and prognosis of recurrent sacral chordomas.Thirty-four patients with recurrent sacral chordomas from 1979 to 2014 were included in this study. The patients comprised 25 men and 9 women with an average age of 50.7 (24-75) years. The average time until recurrence was 19.4 (4-51) months postoperatively, and 85.3% of the recurrent tumors were located in bone. The patients had an average of 1.2 (1-3) recurrences before further operations were performed in our hospital. The mean maximum tumor diameter was 8.1 (4.6-12.0) cm. Thirty-one patients underwent further tumor resection in our hospital. The postoperative recurrence, metastasis, and survival results were followed and analyzed.The mean follow-up after surgical treatment of recurrence was 49.6 (12-144) months. Nine patients (37.5%) developed recurrence again after an average of 26.7 months. The 3-year and 5-year recurrence-free survival rate was 69.4% and 63.1%, respectively. Multivariate analysis showed that the tumor level within the sacrum (P = .001) and the surgical margin (P = .001) were significant recurrence-related factors. Four patients (16.7%) developed lung metastasis. Eighteen patients were alive at last follow-up. The 5-year and 10-year survival rate after surgical treatment of recurrence was 67.3% and 53.9%, respectively.Most recurrent tumors are located in bone, and a safe osteotomy margin is important. The surgical margin is the only controllable factor of further tumor recurrence. Some patients with recurrence achieve long survival and obtain a clinical benefit from repeated operations if complete resection is achieved.
分析复发性骶骨脊索瘤进一步手术治疗的临床结果及相关因素。脊索瘤是罕见的原发性恶性肿瘤,复发率高。复发性肿瘤的治疗困难且存在争议。既往手术造成的污染以及局部解剖结构紊乱可能增加再次手术的风险。既往大多数研究都集中在原发性肿瘤;关于复发性骶骨脊索瘤的临床诊断、治疗及预后的报道极少。
本研究纳入了1979年至2014年期间的34例复发性骶骨脊索瘤患者。患者包括25例男性和9例女性,平均年龄50.7(24 - 75)岁。术后至复发的平均时间为19.4(4 - 51)个月,85.3%的复发性肿瘤位于骨内。在我院进行进一步手术前,患者平均复发1.2(1 - 3)次。肿瘤平均最大直径为8.1(4.6 - 12.0)cm。31例患者在我院接受了进一步的肿瘤切除手术。对术后复发、转移及生存结果进行了随访和分析。
复发手术治疗后的平均随访时间为49.6(12 - 144)个月。9例患者(37.5%)平均在26.7个月后再次复发。3年和5年无复发生存率分别为69.4%和63.1%。多因素分析显示,骶骨内肿瘤水平(P = 0.001)和手术切缘(P = 0.001)是与复发显著相关的因素。4例患者(16.7%)发生肺转移。末次随访时18例患者存活。复发手术治疗后的5年和10年生存率分别为67.3%和53.9%。
大多数复发性肿瘤位于骨内,安全的截骨切缘很重要。手术切缘是进一步肿瘤复发的唯一可控因素。部分复发患者若能实现完整切除,可通过反复手术获得长期生存并从中获益。